Geographic Atrophy clinical trials at UCSF
2 in progress, 1 open to eligible people
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
open to eligible people ages 55 years and up
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
San Francisco, California and other locations
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Sorry, not currently recruiting here
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
San Francisco, California and other locations